(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement regarding a white paper released today by the American Diabetes Association on insulin prices: “The American Diabetes Association’s new white paper on insulin prices confirms that drugmakers set, and
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health plan doesn’t use a pharmacy benefit company? A recent Department of Labor (DOL) Office of the
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health plan doesn’t use a pharmacy benefit company? A recent Department of Labor (DOL) Office of the
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost, that quantifies what a world without pharmacy benefit companies would look like for employers and
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
Today, Thursday March 9, The Hill is hosting an important conversation titled: “Prescription for Change: Improving Competition to Lower Drug Prices,” featuring: David Schweikert (R-AZ), Member, Ways & Means Committee Tina Smith (D-MN), Member, Senate HELP Committee Lauren Aronson, Executive
Thanks to PBMs’ efforts to give patients an incentive to use them and pharmacies an incentive to purchase them at the lowest prices, generics are widely available and affordable for hundreds of millions of Americans.
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
This practice, the HHS inspector general said, could harm patients, the government and taxpayers because people might take pricey drugs instead of cheaper ones.
PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
©2024 PCMA. All Rights Reserved.
